David W. Boulton - Publications, H-index & Citations

David W. Boulton

clinical pharmacology

45H指数

200论文数

7.1K被引数

收录论文 93

发表时间

Eosinophilic Depletion with Benralizumab; Mepolizumab; and Depemokimab: A Modeling Study 嗜酸性粒细胞耗竭与Benralizumab、Mepolizumab和Depemokimab：一项建模研究

Journal of Asthma and Allergy

IF3

2026-05-19

OAAI

Pradeep B Lukka; Robert C Penland; Ari Brekkan; Rami Ayoun Alsoud; Sherri So; David W Boulton

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration 抑制OATP1B1/3而非UGT1A1可能是阿扎那韦给药后胆红素升高的主要原因

Clinical Pharmacology & Therapeutics

IF5.5

2024-12-14

OAAI

Jin Dong; Pradeep Sharma; Rasha Emara; Derek Cheung; Weifeng Tang; Diansong Zhou; David W. Boulton; Mats Någård; Miki S. Park

Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-10-03

OAAI

Sharma, Pradeep; Boulton, David W.; Bertagnolli, Lynn N.; Tang, Weifeng

Racial Comparison of the Pharmacokinetics and Safety of Fixed-dose Combination of Dapagliflozin/Sitagliptin in Western and Korean Healthy Adults

CLINICAL THERAPEUTICS

IF3.6

2024-09-01

PREAI

Lukka, Pradeep B.; Tang, Weifeng; Hammarstedt, Ann; Conrad, Tom; Heijer, Maria; Karlsson, Cecilia; Boulton, David W.

The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2024-08-19

OAAI

Yu, Hongtao; Greasley, Peter J.; Heerspink, Hiddo J. Lambers; Ambery, Philip; Ahlstrom, Christine; Hamren, Bengt; Khan, Anis A.; Boulton, David W.; Hallow, K. Melissa

A literature review of drug transport mechanisms during lactation

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-07-07

OAAI

Gong, Christine; Bertagnolli, Lynn N.; Boulton, David W.; Coppola, Paola

Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-12-04

OAAI

Clegg, Lindsay E.; Chu, Lulu; Nagard, Mats; Boulton, David W.; Penland, Robert C.

A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons 因药代动力学原因对妊娠相关用药方案进行临床干预的系统评价

FRONTIERS IN MEDICINE

IF3

2023-11-29

OAAI

Borda, Lauren A.; Nagard, Mats; Boulton, David W.; Venkataramanan, Raman; Coppola, Paola

Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus 射血分数降低的心力衰竭患者和2型糖尿病患者之间的达格列净药代动力学相似

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-11-20

PREAI

Melin, Johanna; Parkinson, Joanna; Hamren, Bengt; Penland, Robert C.; Boulton, David W.; Tang, Weifeng

A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy

PHARMACEUTICS

IF5.5

2023-11-15

OAAI

Gong, Christine; Bertagnolli, Lynn N.; Boulton, David W.; Coppola, Paola

Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-release Fixed-dose Combination in Healthy Chinese Volunteers and Regional Comparison

CLINICAL THERAPEUTICS

IF3.6

2023-08-01

OAAI

Zhao, Xiaoying; Ning, Rui; Hui, Andrew; Boulton, David W.; Tang, Weifeng

Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-05-01

PREAI

Reig-Lopez, Javier; Tang, Weifeng; Fernandez-Teruel, Carlos; Merino-Sanjuan, Matilde; Mangas-Sanjuan, Victor; Boulton, David W.; Sharma, Pradeep

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-03-16

OAAI

Sokolov, Victor; Yakovleva, Tatiana; Stolbov, Leonid; Penland, Robert C.; Boulton, David; Parkinson, Joanna; Tang, Weifeng

Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-01-17

OAAI

Coutant, David E.; Boulton, David W.; Dahal, Upendra P.; Deslandes, Antoine; Grimaldi, Christine; Pereira, Joao N. S.; Saell, Carolina; Sarvaiya, Hetal; Schiller, Hilmar; Tai, Guoying; Umehara, Kenichi; Yuan, Yang; Dallas, Shannon

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF

EUROPEAN JOURNAL OF HEART FAILURE

IF10.8

2022-08-22

OAAI

Adamson, Carly; Cowan, Lorna M.; de Boer, Rudolf A.; Diez, Mirta; Drozdz, Jaroslaw; Dukat, Andre; Inzucchi, Silvio E.; Kober, Lars; Kosiborod, Mikhail N.; Ljungman, Charlotta E. A.; Martinez, Felipe A.; Ponikowski, Piotr; Sabatine, Marc S.; Lindholm, Daniel; Bengtsson, Olof; Boulton, David W.; Greasley, Peter J.; Langkilde, Anna Maria; Sjostrand, Mikaela; Solomon, Scott D.; McMurray, John J., V; Jhund, Pardeep S.

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-01-23

OAAI

Naagaard, M. Daniel; Chang, Roy; Nagard, Mats; Tang, Weifeng; Boulton, David W.

Evolving drug regulatory landscape in China: A clinical pharmacology perspective

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-02-23

OAAI

Tang, Weifeng; Huang, Ying; Zhou, Diansong; Huang, Yao; Chen, Yingxue; Ren, Song; Li, Yan; Wu, Shengqian; Zhao, Xiaoying; Song, Xuyang; Wang, Haidong; Jin, Yuwen; Yu, Hongtao; Zhang, Li; Li, Yunfei; Boulton, David; Shen, Kevin

Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials

DIABETES OBESITY & METABOLISM

IF5.7

2021-02-02

PREAI

Clegg, Lindsay E.; Jing, Yankang; Penland, Robert C.; Boulton, David W.; Hernandez, Adrian F.; Holman, Rury R.; Vora, Jiten

A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2021-01-25

PREAI

Shah, Millie; Stolbov, Leonid; Yakovleva, Tatiana; Tang, Weifeng; Sokolov, Victor; Penland, Robert C.; Boulton, David; Parkinson, Joanna